Detalhe da pesquisa
1.
Multicenter, Open-Label, Phase II Study of Bendamustine and Rituximab Followed by 90-Yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe).
Clin Cancer Res
; 25(20): 6073-6079, 2019 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31243122